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Abstract 
As the median age of deceased kidney donors rises, updated knowledge of transplant 
outcomes from older deceased donors in differing donor-recipient age groups is required. 
Using ERA-EDTA Registry data we determined survival outcomes of kidney allografts donated 
from the same older deceased donor (55-70 years), and transplanted into one recipient 
younger and one recipient of similar age to the donor. The recipient pairs were divided into 
two groups: group 1; younger (median age: 52 years) and older (60 years), and group 2; 
younger (41 years) and older (60 years). 1,410 adults were transplanted during 2000-2007. 
Compared to the older recipients the mean number of functioning graft years at 10-years was 
six months longer in the group 1 and group 2 younger recipients (p<0.001). Ten-year graft 
survival was 54% and 40% for the group 1 younger and older recipients, and 60% and 49% for 
the group 2 younger and older recipients. Paired Cox regression analyses showed a lower risk 
of graft failure (group 1 younger; adjusted relative risk [RRa]:0.57, 95%CI:0.41-0.79, and group 
2 younger; RRa:0.63, 95%CI:0.47-0.85) in younger recipients. Outcomes from older deceased 
donor allografts transplanted into differing donor-recipient age groups are better than 
previously reported. These allografts remain a valuable transplant resource, particularly for 
similar-aged recipients. 
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Introduction 
Global variations exist in the criteria for deceased donor kidney allocation (1). Some  
European deceased donor kidney allocation schemes such as that of the UK, Spain, France 
and Scandiatransplant take into consideration the age difference between the donor and the 
potential recipient, whereas others such as Eurotransplant do not (for patients aged <65 
years) (1). Deceased donor kidney allocation algorithms that are designed to account for the 
age difference between the donor and the potential recipient, will where possible allocate 
younger kidneys to younger patients and older kidneys to older patients (2). However the 
definition of an acceptable donor-recipient age difference also varies between allocation 
schemes, for example in Italy a difference between the donor and recipient ages of less than 
15 years is preferred, whereas in Spain a difference of less than 10 years is preferred. Whilst 
allocation schemes may take the donor-recipient age difference into account, older donor 
kidneys are still being allocated to patients of various ages. 
The rationale of age-matching is two-fold; firstly by matching the potential lifespan of 
the allograft with the recipient, the organ is used efficiently. Secondly, young recipients 
receiving old deceased donor kidneys have been shown to have worse graft survival 
outcomes including higher rates of graft failure from rejection compared to young recipients 
receiving young deceased donor kidneys (3-6). However many of these previous studies were 
performed in the 1990s and early 2000s when the median age of both the donors and 
recipients were lower, and graft survival outcomes were worse.  
Over the past two decades the demand for transplantable organs has resulted in an 
increased utilisation of older ‘marginal’ deceased donor kidneys. Subsequently the median 
age of deceased kidney donors has steadily increased (7, 8). Within Northern Europe the 
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median age of deceased kidney donors has risen from approximately 35 years in the 1990s to 
approximately 55 years in 2015 (9, 10). As the median age of deceased kidney donors and 
their recipients is now approximately 55 years old, and transplant outcomes over the past two 
decades have improved (11), updated patient and allograft survival outcomes of kidneys 
transplanted from deceased donors aged 55 years and over (i.e. above the median deceased 
donor age) into recipients of differing ages are required.  
Using renal registry and transplant registry data from nine European 
countries/regions, the aim of this study was quantify how long kidney allografts from older 
deceased donors are expected to function for whilst considering the donor-recipient age 
difference. Using a paired analysis study design, we analysed patient and allograft survival 
outcomes of two kidney allografts donated from the same deceased donor aged between 55 
to 70 years, and transplanted into two recipients of differing ages; a recipient younger than 
the donor and a recipient of similar age to the donor. This method ensures that a kidney from 
the same donor is present in both groups, thereby eliminating from the analyses the effects of 
the donor factors on patient and graft outcomes. Furthermore, we used a novel technique 
within the kidney transplantation literature, the restricted mean survival time, to quantify the 
mean difference in the graft survival time between the groups (12).  
 
Materials and Methods  
Data collection and study groups 
Renal and transplant registries within nine European countries or regions supplying data to 
the European Renal Association – European Dialysis and Transplant Association (ERA-EDTA) 
Registry were asked to identify transplant recipients fulfilling the specified inclusion criteria 
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(see below). Where necessary additional data required for the survival analyses were 
obtained from the ERA-EDTA Registry database using a unique anonymised patient identifier 
(see table 1 for data sources).  
The study cohort consisted of all patients aged 18 years and over who received their first 
kidney only transplant between 2000 and 2007 from a deceased donor aged between 55 to 
70 years. As the median deceased donor age in many European countries is 55 years, the age 
range 55 to 70 was specifically chosen to reflect donors just above the average age of 
deceased donation. Only cases where both kidneys from the same deceased donor were 
transplanted into recipients of differing ages were considered. One transplant recipient had 
to be within 5 years of the donor’s age (as these recipients had a median age at 
transplantation above the current median transplant age we called these recipients the older 
recipients), and the second transplant recipient from the same deceased donor had to be at 
least 6 years or more younger than the donor. Given the large range of the donor-recipient 
age gradient, that is, the difference in years between the donor and recipient ages, we 
subdivided the recipient pairs into two groups; termed group 1 and group 2. The cut-off point 
for the two groups was determined pre-analysis using univariate Cox regression with 
restricted cubic regression splines analysis (13). The groups were those ≥6 to <13 years 
younger than the donor and their paired older recipients (group 1) and those ≥13 years 
younger than the donor and their paired older recipients (group2). The Chi-squared test and 
Mann-Whitney U test were used to compare the group characteristics. 
 
Statistical analyses 
 9 
 
Table 2 provides an overview of the different survival analyses used in this paper, i.e. the 
survival outcome investigated and analysis method used, the starting point, the event(s) of 
interest, competing event(s), censoring observations and the potential confounders 
accounted for in the multivariable analysis. In all of the survival analyses the date of kidney 
transplantation was taken as the starting point of the analysis, and patients were followed 
until the event of interest, a censored observation and/or a competing event (see Table 2 for 
details) or the end of the follow-up period (31st December 2013).  
 
Restricted mean number of functioning graft years 
The restricted mean survival is a way in which one quantifies the mean survival of a treatment 
group measured up to a specific time point. It is computed as the total area under the 
covariate-adjusted graft survival curve up to a specific time point. By comparing the mean 
survival of two groups one obtains an assessment of a treatment effect over a time interval 
(12). This method has the advantages of being relatively easy to understand and can be used 
even in the presence of non-proportional hazards (14). We estimated the restricted mean 
survival time of functioning graft years (i.e. the number of years the allograft was functional 
before loss secondary to graft failure or death with a functioning graft). We repeated this 
process four times with increasing follow-up times thereby obtaining the mean graft survival 
time restricted to one, five, seven, and ten years of follow-up (12) (i.e. what was the average 
time the older donor kidneys were functional for in one, five, seven, and ten years follow-up). 
We adjusted for important transplant related parameters selected a priori which could 
influence the functioning of the graft, i.e. cold ischaemia time and human leukocyte antigen 
(HLA) mismatch (favourable HLA-A, HLA-B and HLA-DR mismatches: 000, 100, 010, 110 versus 
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all other mismatches). The SAS macro %RESMEAN was used for this analysis (12). 
 
Cumulative risk of graft failure 
The cumulative incidence competing risk method was used to estimate the unadjusted 10-
year cumulative risk of graft failure and death (15).  
 
Relative risk of allograft failure and patient mortality between younger and older recipients 
Cox regression was used to estimate the relative risk of graft failure (defined as graft loss from 
all causes or death with a functioning graft) (16), and the relative all-cause mortality risk 
between the older recipient group and the corresponding younger recipient group. 
Furthermore, Cox regression analysis was used to estimate the relative risk of graft failure in 
which the competing event of death was interpreted as a censored event (15) (henceforth 
termed death-censored graft failure). All Cox regression analyses were stratified by the donor 
pair, whereby the patient or kidney allograft outcome of the older recipient 
was directly compared to the patient or kidney allograft outcome of the younger recipient 
from the same older deceased donor. This removed any donor associated factors from the 
analysis. Adjustments were made in a step-wise manner. Firstly, we only adjusted for 
transplant related parameters which could influence graft survival, i.e. cold ischaemia time 
and HLA mismatch. Secondly, we added recipient factors which could influence graft survival, 
i.e. recipient sex, primary renal disease and initial modality of renal replacement therapy.  
A two-tailed p-value of less than 0.05 was considered statistically significant. Analyses were 
performed using SAS version 9.3 and R version 3.0.2. 
 
 11 
 
Results 
Baseline characteristics 
In total 1,410 paired kidney transplant recipients from 705 deceased donors aged between 55 
to 70 years were included in the study (Table 3). The recipients in group 1 consisted of the 
younger recipients which were within ≥6 to <13 years of the donor’s age (N=336), termed 
group 1 younger recipients and their corresponding paired older recipients which were within 
5 years of the same deceased donor’s age (N=336), termed group 1 older recipients, and the 
recipients in group 2 consisted of the younger recipients which were ≥13 years younger than 
the donor (N=369), termed group 2 younger recipients and their corresponding paired older 
recipients which were within 5 years of the same donor’s age (N=369), termed group 2 older 
recipients. 
Table 3 shows the baseline characteristics of the recipient groups and the 
corresponding donor details. The median donor-recipient age gradient was 8.1 years 
(interquartile range [IQR] 7.0 to 10.0) for the group 1 younger recipients, and 20 years (IQR 
16.0 to 25.5) for the group 2 younger recipients, whereas both groups of paired older 
recipients were 0.9 years (IQR -2.0 to 3.0) younger than the donor. The median age at kidney 
transplantation was 52.0 years (IQR 49.0 to 56.3) for the group 1 younger recipients and 40.7 
years (IQR 34.0 to 45.0) for the group 2 younger recipients. The median age of the older 
recipients in both groups was 60.0 years (IQR 57.0 to 64.0). At the time of donation the 
deceased donors donating to group 1 had a median age of 61.0 years (IQR 58.0 to 65.0) and 
the deceased donors donating to group 2 had a median age of 60.0 years (IQR 57.0 to 63.0).  
 
Restricted mean number of functioning graft years 
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Table 4 shows the restricted mean number of functioning graft years i.e. the number of years 
the allograft was functional before loss secondary to graft failure or death with a functioning 
graft. Restricted to 1 year of follow-up there was no difference in the mean number of 
functioning graft years between the younger and older recipients in group 1 and the younger 
and older recipients in group 2. The difference in the mean number of functioning graft years 
between the younger and older recipients in both groups increased with the duration of 
follow-up. By 10 years follow-up the difference in the mean number of functioning graft years 
was 0.45 (95% confidence interval [CI]: 0.18 to 0.72, i.e. 5.4 months) and 0.52 (95%CI: 0.27 to 
0.77, i.e. 6.2 months longer) years longer in the group 1 younger and group 2 younger 
recipients respectively compared to their paired older recipients (p<0.001). 
 
Cumulative risk of graft failure 
Figure 1 shows the 10-year cumulative risk of graft failure from all causes i.e. graft failure and 
death with a functioning graft for group 1 (upper panel) and group 2 (lower panel). The 10-
year cumulative risk of graft failure from all causes was 46% and 60% for the group 1 younger 
and older recipients respectively, and 40% and 51% for the group 2 younger and older 
recipients respectively. 
 
Risk of allograft failure and patient survival  
The risk of graft failure (defined as either graft failure or death with a functioning graft) was 
43% and 37% lower in the group 1 and group 2 younger recipients respectively relative to 
their paired older recipients (Table 5). However, there was a similar risk of death-censored 
graft failure in the group 1 and group 2 younger recipient groups compared to their paired 
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older recipients (Table 5). This reflected the fact that the risk of patient death was 
considerably lower in both younger recipient groups (Table 5).  
 
Discussion  
In this study we have compared the survival outcomes of kidney allografts from older 
deceased donors whilst considering the donor-recipient age difference. We examined the 
outcomes of kidney allografts from the same deceased donor aged between 55 to 70 years 
(median age of 60 years) transplanted into younger recipients (group 1 with a median of age 
52 years or group 2 with a median age of 41 years) with the outcomes when transplanted into 
an “older” recipient (similar age as donor; median age of 60 years). By performing a paired 
analysis whereby a donor kidney is present in the younger recipient group and in the 
corresponding older recipient group, the effects of the donor factors on patient and graft 
outcomes are essentially eliminated from the analyses. In addition, this study used a method 
novel in kidney transplantation, whereby graft survival time was derived using the restricted 
mean survival time. This technique provides easily interpretable and comparable estimates of 
the number of functioning graft years gained or lost by a treatment over a specified time 
interval (12, 17). By using the restricted mean survival time method, we found that by 10 
years of follow-up the mean number of functioning graft years was six months longer in the 
younger recipients compared to the corresponding paired older recipients. We found the 10-
year graft survival from old deceased donor kidneys to be 54% and 40%, for the group 1 
younger and older recipients respectively and 60% and 49% for the group 2 younger and older 
recipients respectively. This is much higher than the previously reported survival probabilities 
of 24% at 8 years in recipients aged <55 years of allografts from deceased donors aged ≥55 
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years (18) and consistent with other studies showing improvements in graft survival within 
European populations over time (11). In contrast to prior studies we found a similar risk of 
death-censored graft failure between the younger recipients compared to the older recipients 
of old deceased donor kidneys. 
 
The 10-year survival probabilities of older deceased donor kidneys reported in this study are 
higher than the previously quoted survival probabilities (4-6, 18). For example Lim et al., 
reported that for allografts from donors aged ≥55 years, eight year cumulative incidence of 
death-censored graft failure was 22.3% and 16.4% in recipients aged <55 years and ≥55 years 
respectively (5). The majority of the previously quoted survival probabilities arise from studies 
predominantly published in the early 2000s using transplant data from the 1990s (6). Survival 
probabilities from deceased donors overall (i.e. not stratified by donor age) have improved 
since the 1990s (11). This probably explains why our survival probabilities from transplants 
that occurred between 2000 and 2007 are better.  
When compared to the current overall European 10-year deceased donor graft 
survival outcomes, our results are worse. Our 10-year graft survival outcomes from deceased 
donors aged between 55 to 70 years are approximately 10% lower than the for overall 
European deceased donor kidney transplant recipients transplanted in the same time period 
(10-year graft survival probabilities of 71%, 65% and 54%, for a median recipient transplant 
age of 41, 50 and 60 years respectively -unpublished data from the European Renal 
Association – European Dialysis and Transplant Association [ERA-EDTA] Registry). There are 
several physiological changes in the older deceased donor kidney which may explain in part, 
the lower graft survival probabilities obtained in comparison to the overall graft survival 
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probabilities for European deceased donor kidney transplant recipients. At the time of 
transplantation older deceased donor kidneys have been shown to have a reduced number of 
nephrons (19) and evidence of age-related pathology (20). Furthermore older deceased donor 
kidneys are not able to mount an adequate repair response following an injury (21). These 
features also render older deceased donor kidneys more susceptible to the effects of longer 
cold ischaemia times (22). Although these features in part explain the lower graft survival 
outcomes we obtained in comparison to the overall graft survival outcomes for European 
deceased donor kidney transplant recipients, active efforts to reduce cold ischaemia times, in 
addition to other advances in the procurement of organs and in transplant medicine overall 
may explain why these results are higher than the historical results. Furthermore, in contrast 
to prior studies we found a similar risk of death-censored graft failure between younger 
recipients compared to older recipients of old deceased donor kidneys. The prior studies from 
the 1990s and 2000s often reported an inferior death-censored graft survival in younger 
recipients of older donor kidneys (5, 18, 23). As with the improvements in 10-year graft 
survival these new findings may also be explained by developments in transplant medicine 
such as organ procurement, transplant preservation and improved immunosuppression 
medication. Despite the approximately 10% lower survival probability by 10 years follow-up 
with older donor kidneys, one must remain aware of the benefits of transplantation over 
dialysis, including improved recipient quality of life and a lower long-term financial burden.   
It should be noted that the 10 year transplant outcomes presented in this study are 
inevitably, a consequence of donations which occurred approximately 10 to 15 years ago. 
Short term transplant outcomes from older deceased donors have improved in the last few 
years (6, 24). It is therefore also likely that the 10 year transplant outcomes in a recipient of 
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an older deceased donor kidney transplanted today will be better than what we present in 
this paper.  
 
The restricted mean survival time provides an alternative way with which to present time to 
an event/survival data. One of the benefits of this method is that the result, often expressed 
in terms of years gained or lost in comparison to an alternative treatment, is easily 
interpretable for physicians and patients alike. Within the kidney transplant literature we 
identified one other study using this method to examine kidney allograft survival in older 
deceased donor kidneys (5). Lim et al., presented mean functioning graft years restricted to 
16 years follow-up of 7.1 years for old recipients (≥55 years) of old donor kidneys ( ≥55 years) 
(5). In other words for sixteen years follow-up, the mean functioning graft survival time was 7 
years, whereas the mean functioning graft years in our study was between 7 and 7.5 years 
within a shorter follow-up of 10 years. The cohort used in the study by Lim et al., were 
transplanted between 1991 and 2006 and therefore the inclusion of transplant outcomes 
from the 1990s is the likely explanation for the poorer outcomes seen in their study.  
 
This study was not designed to compare survival outcomes of young recipients receiving 
either young donor kidneys or old donor kidneys. It is well documented that survival 
outcomes are better for younger recipients if they receive younger donor kidneys (25). 
Furthermore, younger patients are likely to undergo re-transplantation therefore it is 
recommended that they should not receive older donor kidneys given the shorter graft 
survival time and associated risk of sensitization (6). Nevertheless, as shown in this study, 
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kidney transplantations from older donors into younger recipients do take place, as such, it is 
important to quantify the survival outcomes of these allografts.  
 
This study is subject to the traditional limitations associated with observational studies, in 
particular the inability to control for other potential confounding factors. We lacked 
information on other donor factors which contribute to the risk of graft loss such as donor 
history of diabetes and cause of death. However, by performing a paired analysis, a kidney 
from the same older deceased donor was present in the young recipient and the older 
recipient group. We thereby attempted to eliminate any donor associated factors which may 
have resulted in bias. However one cannot be completely sure that even though the donor 
was the same, the kidneys were identical, for example there may have been disparities in 
kidney size or the presence of cysts between the two kidneys. Although both groups of paired 
older recipients, i.e. those paired to the younger recipients in group 1 or group 2 had the 
same median age, there were differences between the groups; of those paired to the group 1 
younger recipients (with a median age of 52 years) only 3% had a pre-emptive transplant, 
compared to 9% of the older recipients paired to the group 2 younger recipients (with a 
median age of 41). Moreover, the graft survival at 10 years follow-up was lower in the older 
recipients paired with the group 1 younger recipients compared to the older recipients paired 
to the group 2 younger recipients (40% versus 49% respectively). This may imply that 
clinicians selectively allocate the ‘better quality’ older deceased donor kidneys to the younger 
recipients and to the healthier older recipients. Therefore the study design employed by this 
study to overcome the limited donor details available to us, may have introduced a selection 
bias into the study. As such, these results cannot be considered generalizable to all donor 
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kidneys from deceased donors aged between 55 to 70 years. We did not have access to 
transplant factors known to influence allograft outcomes such as the method of graft 
preservation, panel reactive antibodies and immunosuppression data, or information 
detailing episodes of delayed graft function or acute rejection therefore we do not know how 
many episodes each group experienced or the impact of these events. Nor do we have an 
accurate record of the causes of graft loss. Despite these limitations there are a number of 
strengths in this study including the paired donor design, the relatively large cohort of 
recipients from a nine European countries/regions and the reasonably long follow-up time. 
Furthermore, the novel restricted mean survival time method used in this study provides 
easily interpretable estimates of the number of years gained or lost or the percentage 
reduction of expected restricted mean survival time.  
 
Conclusion 
The aim of this study was to quantify how long kidney allografts from older deceased donors 
are expected to function for whilst considering the donor-recipient age difference. In line with 
kidney transplant outcomes overall, ten year graft survival probabilities from older deceased 
donors have improved, though they remain approximately 10% lower than the European 
average kidney transplant survival probabilities. Compared to the older recipients the mean 
number of functioning graft years at 10 years was six months longer in the younger recipients. 
Older deceased donor kidneys remain a useful transplant resource, particularly for similar 
aged recipients.
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Figure and table legends 
Figure 1 Ten-year cumulative risk of graft failure from all causes (i.e. graft failure and death) 
for the group 1 younger recipients and their paired older recipients (upper panel a & b) and 
the group 2 younger recipients and their paired older recipients (lower panel c & d). 
 
Table 1 Additional data sources and number of recipients provided by country or region. 
 
Table 2 Overview of the different types of survival analyses used in this paper. The 
adjustments were made in a step-wise manner; (1) transplant related parameters influencing 
graft survival, i.e. cold ischaemia time (CIT) and human leukocyte antigen mismatch (HLA MM) 
and (2) recipient factors influencing graft survival, i.e. recipient sex, primary renal disease and 
initial modality of renal replacement therapy. 
 
Table 3 Baseline characteristics of the group 1 and group 2 younger recipients and their 
paired older recipients and the corresponding donor details. (RRT: Renal replacement 
therapy. HLA: human leukocyte antigen mismatch [favourable HLA-A, HLA-B and HLA-DR 
mismatches: 000, 100, 010, 110]. IQR: inter-quartile range) 
 
Table 4 Mean number of functioning graft years (95% confidence interval) for the group 1 and 
group 2 younger and older recipients respectively. Adjusted for cold ischaemia time and 
human leukocyte antigen mismatch. Differences highlighted in bold indicate a significant 
difference (p<0.05). 
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Table 5 Relative risk (RR) of death-censored graft failure, graft failure and patient mortality for 
the group 1 and group 2 younger recipient groups as compared to their paired older 
recipients. *Adjusted for cold ischaemia time and human leukocyte antigen (HLA) mismatch. 
** Adjusted for cold ischaemia time, HLA mismatch, recipient sex, primary renal disease and 
initial modality of renal replacement therapy. Differences highlighted in bold indicate a 
significant difference (p<0.05). 
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Table 1 Additional data sources and number of recipients provided by country or region 
Country / Region 
supplying data 
Data source(s) 
Number of 
recipients 
Proportion (%) 
Austria Austrian dialysis and transplant registry 90 6.4 
Basque country 
(Spain) 
Information unit about renal patients from the Basque 
Country 
58 4.1 
Catalonia (Spain) Catalan Renal Registry, Catalan Transplant Organization, 
Health Department, Generalitat of Catalonia 
182 12.9 
Denmark Danish Renal Registry and Scandiatransplant  46 3.3 
Finland Finnish Registry for Kidney Diseases and the Finnish 
Kidney Transplant Registry 
96 6.8 
the Netherlands Dutch transplant foundation 138 9.8 
Norway Norwegian Renal Registry 38 2.7 
Sweden Swedish Renal Registry and Scandiatransplant 96 6.8 
United Kingdom United Kingdom Renal Registry and UK Transplant 
Registry held by NHS Blood and Transplant 
666 47.2 
Total  1410 100 
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Table 2 Overview of the different types of survival analyses used in this paper. The adjustments were made in a step-wise manner; (1) 
transplant related parameters influencing graft survival, i.e. cold ischaemia time (CIT) and human leukocyte antigen mismatch (HLA MM) and 
(2) recipient factors influencing graft survival, i.e. recipient sex, primary renal disease and initial modality of renal replacement therapy. 
Survival analysis outcome  Survival analysis method Starting point Event of interest Competing event  Censoring observations Variables adjusted 
for  
Cumulative risk of graft 
failure 
Cumulative incidence 
competing risk method 
Date of kidney 
transplant 
Graft failure  Death with a 
functioning graft* 
 
End of follow-up period 
Loss to follow-up 
 
 
Restricted mean number 
of functioning graft years 
Area under the estimated 
graft survival function  
Date of kidney 
transplant 
Graft failure 
or 
Death with a 
functioning graft 
 End of follow-up period or  
End of 10 year follow-up; 
whichever event occurred first 
Loss to follow-up 
CIT, HLA MM 
Relative risk of death-
censored graft failure 
between paired recipients 
Pair-stratified Cox 
regression (cause-specific 
model) 
Date of kidney 
transplant 
Graft failure  Death with a functioning 
graft**  
End of follow-up period  
Loss to follow-up 
1. CIT & HLA MM.  
2. CIT, HLA MM, 
recipient sex, PRD & 
first RRT modality 
Relative risk of graft 
failure between paired 
recipients 
Pair-stratified Cox 
regression  
Date of kidney 
transplant 
Graft failure 
or 
Death with a 
functioning graft 
 End of follow-up period 
Loss to follow-up 
1. CIT & HLA MM.  
2. CIT, HLA MM, 
recipient sex, PRD & 
first RRT modality 
Relative risk of mortality 
between paired recipients 
Pair-stratified Cox 
regression 
Date of kidney 
transplant 
Patient death  End of follow-up period 
Loss to follow-up 
1. CIT & HLA MM.  
2. CIT, HLA MM, 
recipient sex, PRD & 
first RRT modality 
HLA MM: human leukocyte antigen mismatch. CIT: cold ischaemia time. PRD: primary renal disease. RRT: renal replacement therapy. End of follow-up period: 31st December 
2013 
* Using the cumulative incidence competing risk method, “death with a functioning graft” was interpreted as a competing event.  
**Using the pair-stratified cause-specific Cox regression, “death with a functioning graft” was interpreted as a censored event (15) 
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Table 3 Baseline characteristics of the group 1 and group 2 younger recipients and their paired older 
recipients and the corresponding donor details. (RRT: Renal replacement therapy. HLA: human 
leukocyte antigen mismatch [favourable HLA-A, HLA-B and HLA-DR mismatches: 000, 100, 010, 110]. 
IQR: inter-quartile range) 
 Group 1 Group 2  
 
Younger  
recipients,        
(≥6 to <13 years 
younger) 
Older recipients p-value 
Younger 
recipients,             
(≥13 years 
younger) 
Older recipients p-value 
Missing 
data (%) 
all 
groups 
Number 336 336  369 369   
Recipient sex (% male) 63.4 64.3 0.81 63.1 68.0 0.16 0 
Age at transplantation, years 
(median, IQR) 
52.0 (49.0, 56.3) 60.6 (57.0, 64.0) <0.01 40.7 (34.0, 45.0) 60.0 (56.7, 63.6) <0.01 0 
Pre-transplant dialysis time, 
years (median, IQR) 
2.1 (1.1, 3.9) 2.5 (1.3, 4.0) 0.51 2.4 (1.2, 4.2) 2.5 (1.4, 4.1) 0.78 0 
First RRT modality (%);   0.22   0.29 0.1 
haemodialysis 66.4 69.1  58.3 59.6   
peritoneal dialysis 28.0 28.0  35.5 30.9   
pre-emptive transplant 5.7 3.0  6.0 9.2   
Primary renal disease (%);   0.25   0.02 Unknown
= 
diabetes mellitus 14.3 15.5  10.3 9.5  16.7% 
hypertension/renovascular 9.2 10.4  6.8 9.2   
glomerulonephritis/sclerosis 19.4 24.4  27.9 19.0   
Other (including unknown) 57.1 49.7  55.0 62.3   
Donor age, years (median, IQR) 61.0 (58.0, 65.0) 61.0 (58.0, 65.0) NA 60.0 (57.0, 63.0) 60.0 (57.0, 63.0) NA 0 
Donor recipient age gradient, 
years (median, IQR) 
8.1 (7.0, 10.0) 0.9 (-2.0, 3.0) <0.01 20.0 (16.0, 25.5) 0.9 (-2.0, 3.0) <0.01 0 
Donor type (%);   NA   NA 0 
donation after brain death 89.6 89.6  90.5 90.5   
donation after cardiac death 10.4 10.4  9.5 9.5   
Cold ischaemia time, hrs      
(median, IQR) 
18.4 (15.0, 23.0) 18.0 (15.2, 21.9) 0.49 20.0 (16.0, 25.5) 19.0 (15.7, 23.3) 0.18 14.0 
HLA mismatch (% favourable 
HLA-A, -B, -DR mismatches) 
30.1 27.4 0.44 40.1 36.3 0.29 0 
Median follow-up time, years 
(IQR) 
7.9 (5.3, 10.3) 7.2 (3.7, 9.9) 0.11 7.4 (4.5, 9.6) 6.9 (3.9, 9.1) 0.47  
Total follow-up time, years  2228.20 2092.23  2571.47 2372.33   
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Table 4 Mean number of functioning graft years (95% confidence interval) for the group 1 and group 2 younger and older recipients 
respectively. Adjusted for cold ischaemia time and human leukocyte antigen mismatch. Differences highlighted in bold indicate a significant 
difference (p<0.05). 
 
 Group 1 Group 2 
Follow-up time 
restricted to: 
Mean number of functioning graft years for the younger 
recipients and the paired older recipients 
Mean number of functioning graft years for the younger 
recipients and the paired older recipients 
Younger  
recipients (95%CI) 
Older recipients 
(95%CI) 
Difference 
(95%CI) 
Younger 
recipients (95%CI) 
 
Older recipients 
(95%CI) 
Difference          
(95%CI) 
1 year 0.92 (0.89, 0.95) 0.91 (0.87, 0.95) 0.02 (-0.03, 0.06) 0.92 (0.89, 0.95) 0.92 (0.89, 0.95) -0.004 (-0.05, 
0.04) 
5 years 4.18 (4.08, 4.28) 4.07 (3.96, 4.17) 0.12 (-0.03, 0.26) 4.24 (4.15, 4.33) 4.09 (3.99, 4.19) 0.15 (0.01, 0.29) 
7 years 5.58 (5.45, 5.71) 5.38 (5.24, 5.52) 0.20 (0.01, 0.39) 5.70 (5.58, 5.82) 5.41 (5.23, 5.54) 0.29 (0.11, 0.47) 
10 years 7.42 (7.24, 7.60) 6.97 (6.77, 7.17) 0.45 (0.18, 0.72) 7.63 (7.47, 7.79) 7.11 (6.94, 7.29) 0.52 (0.27, 0.77) 
 Based on deceased donors with a median age of 61 
(interquartile range, 58-65)  
Based on deceased donors with a median age of 60 
(interquartile range, 57-63) 
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Table 5 Relative risk (RR) of death-censored graft failure, graft failure and patient mortality for the group 1 and group 2 younger recipient 
groups as compared to their paired older recipients. *Adjusted for cold ischaemia time and human leukocyte antigen (HLA) mismatch. ** 
Adjusted for cold ischaemia time, HLA mismatch, recipient sex, primary renal disease and initial modality of renal replacement therapy. 
Differences highlighted in bold indicate a significant difference (p<0.05). 
 
 
Group 1 younger recipients compared to paired older 
recipients 
Group 2 younger recipients compared to paired older 
recipients 
unadjusted RR 
(95%CI) 
adjusted RR* 
(95%CI) 
adjusted RR** 
(95%CI) 
unadjusted RR 
(95%CI) 
 
adjusted RR* 
(95%CI) 
adjusted RR** 
(95%CI) 
Death-
censored graft 
failure 
1.03 (0.71, 1.49) 0.79 (0.52, 1.19) 0.84 (0.54, 1.30) 1.30 (0.95, 1.79) 1.14 (0.81, 1.62) 1.04 (0.72, 1. 50) 
Graft failure 0.69 (0.53, 0.90) 0.60 (0.45, 0.81) 0.57 (0.41, 0.79) 0.79 (0.61, 1.01) 0.67 (0.50, 0.89) 0.63 (0.47, 0.85) 
Patient 
mortality 
0.49 (0.36, 0.66) 0.56 (0.43, 0.71) 0.37 (0.25, 0.54) 0.23 (0.16, 0.34) 0.21 (0.14, 0.30) 0.21 (0.15, 0.31) 
 
 
